Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Sponsor: Neurocrine Switzerland GmbH
Summary
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.
Official title: A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia
Key Details
Gender
All
Age Range
3 Months - 47 Months
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-07-01
Completion Date
2028-03
Last Updated
2026-09-16
Healthy Volunteers
No
Conditions
Interventions
Crinecerfont
Oral solution
Locations (11)
Neurocrine Clinical Site
San Francisco, California, United States
Neurocrine Clinical Site
Aurora, Colorado, United States
Neurocrine Clinical Site
Hartford, Connecticut, United States
Neurocrine Clinical Site
Atlanta, Georgia, United States
Neurocrine Clinical Site
Chicago, Illinois, United States
Neurocrine Clinical Site
Indianapolis, Indiana, United States
Neurocrine Clinical Site
Ann Arbor, Michigan, United States
Neurocrine Clinical Site
Minneapolis, Minnesota, United States
Neurocrine Clinical Site
Philadelphia, Pennsylvania, United States
Neurocrine Clinical Site
Dallas, Texas, United States
Neurocrine Clinical Site
Seattle, Washington, United States